Global Ophthalmoplegia Market

Ophthalmoplegia Comprehensive Study by Type (External Ophthalmoplegia, Internuclear Ophthalmoplegia), Application (Telemedicine Platforms, Assistive Technology Application, Low Vision Aid Apps), End User (Hospital & Clinics, Ambulatory Clinics, Other), Treatment (Surgery, Drug Treatment, Other) Players and Region - Global Market Outlook to 2030

Ophthalmoplegia Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Ophthalmoplegia Market Scope
Ophthalmoplegia is a medical situation where there is weakness or paralysis of the eye muscles i.e. extraocular muscles. There are six muscles which control the eye activities and hold the eye in its place and any one of these muscles can be affected in Ophthalmoplegia. Ophthalmoplegia is also called as Ophthalmoparesis. Person suffering from Ophthalmoplegia can have blurred or double vision. Some of the common causes of Ophthalmoplegia are stroke, thyroid disease and brain injury or trauma. Patients which are suffering from diabetes are slightly at an increased risk for having Ophthalmoplegia. Moreover, Ophthalmoplegia can involve any or all of the extraocular muscles consisting of the inferior recti, lateral recti, superior recti, medial recti, superior oblique and inferior oblique muscles.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAbbott (United States), Novartis AG (Switzerland), Johnson & Johnson (United States), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Topcon Corporation (Japan), Medline Industries, Inc. (United States), Allergan (Ireland), F. Hoffmann-La Roche Ltd (Switzerland) and Santen Pharmaceutical Co., Ltd (Japan)
CAGR8.2%


The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments. Research Analyst at AMA estimates that United States and Japanese Players will contribute to the maximum growth of Global Ophthalmoplegia market throughout the predicted period.

Abbott (United States), Novartis AG (Switzerland), Johnson & Johnson (United States), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Topcon Corporation (Japan), Medline Industries, Inc. (United States), Allergan (Ireland), F. Hoffmann-La Roche Ltd (Switzerland) and Santen Pharmaceutical Co., Ltd (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Nidek Co., Ltd (Japan), HOYA Corporation (Japan), Essilor (France) and Amritt, Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Ophthalmoplegia market by Type , by Application (Telemedicine Platforms, Assistive Technology Application and Low Vision Aid Apps) and Region with country level break-up.

On the basis of geography, the market of Ophthalmoplegia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In April 2023 Abbott announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
In December 2023: Global healthcare company Abbott is taking The Next Chapter campaign on menopause a step forward through new ways to break the silence around the topic. This year, to encourage meaningful menopause conversations, the company introduced a simple, engaging conversation starter, ‘Real, Made up, or Mine?’ at an event held in Mumbai.
On October 22, 2018, IDx, a leading AI diagnostics company, and Topcon, one of the world’s leading ophthalmic device manufacturers, have signed an exclusivity agreement that will allow the companies to scale delivery of AI-based diagnostic solutions

Influencing Trend:
Rapid Developments in Technology Related To Eye Diseases

Market Growth Drivers:
Growing Geriatric Population Worldwide and Rising Prevalence of Eye Sight Affecting Diseases

Challenges:
Availability of Alternative Low Cost Treatment

Restraints:
High Price of the Treatment

Opportunities:
Growing Healthcare Expenditure in the Developed Countries

Key Target Audience
Manufacturers of Ophthalmic device, Suppliers of Ophthalmic device parts, Distributers of Ophthalmic device, Healthcare industry, Governmental bodies, Hospitals and clinics, Academic institutes and universities and Research Firms

Report Objectives / Segmentation Covered

By Type
  • External Ophthalmoplegia
  • Internuclear Ophthalmoplegia
By Application
  • Telemedicine Platforms
  • Assistive Technology Application
  • Low Vision Aid Apps
By End User
  • Hospital & Clinics
  • Ambulatory Clinics
  • Other

By Treatment
  • Surgery
  • Drug Treatment
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population Worldwide
      • 3.2.2. Rising Prevalence of Eye Sight Affecting Diseases
    • 3.3. Market Challenges
      • 3.3.1. Availability of Alternative Low Cost Treatment
    • 3.4. Market Trends
      • 3.4.1. Rapid Developments in Technology Related To Eye Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ophthalmoplegia, by Type, Application, End User , Treatment and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Ophthalmoplegia (Value)
      • 5.2.1. Global Ophthalmoplegia by: Type (Value)
        • 5.2.1.1. External Ophthalmoplegia
        • 5.2.1.2. Internuclear Ophthalmoplegia
      • 5.2.2. Global Ophthalmoplegia by: Application (Value)
        • 5.2.2.1. Telemedicine Platforms
        • 5.2.2.2. Assistive Technology Application
        • 5.2.2.3. Low Vision Aid Apps
      • 5.2.3. Global Ophthalmoplegia by: Treatment (Value)
        • 5.2.3.1. Surgery
        • 5.2.3.2. Drug Treatment
        • 5.2.3.3. Other
      • 5.2.4. Global Ophthalmoplegia Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Ophthalmoplegia (Price)
      • 5.3.1. Global Ophthalmoplegia by: Type (Price)
  • 6. Ophthalmoplegia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ZEISS International (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Valeant Pharmaceuticals International, Inc. (US)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Topcon Corporation (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Medline Industries, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Santen Pharmaceutical Co., Ltd (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Ophthalmoplegia Sale, by Type, Application, End User , Treatment and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Ophthalmoplegia (Value)
      • 7.2.1. Global Ophthalmoplegia by: Type (Value)
        • 7.2.1.1. External Ophthalmoplegia
        • 7.2.1.2. Internuclear Ophthalmoplegia
      • 7.2.2. Global Ophthalmoplegia by: Application (Value)
        • 7.2.2.1. Telemedicine Platforms
        • 7.2.2.2. Assistive Technology Application
        • 7.2.2.3. Low Vision Aid Apps
      • 7.2.3. Global Ophthalmoplegia by: Treatment (Value)
        • 7.2.3.1. Surgery
        • 7.2.3.2. Drug Treatment
        • 7.2.3.3. Other
      • 7.2.4. Global Ophthalmoplegia Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Ophthalmoplegia (Price)
      • 7.3.1. Global Ophthalmoplegia by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ophthalmoplegia: by Type(USD Million)
  • Table 2. Ophthalmoplegia External Ophthalmoplegia , by Region USD Million (2018-2023)
  • Table 3. Ophthalmoplegia Internuclear Ophthalmoplegia , by Region USD Million (2018-2023)
  • Table 4. Ophthalmoplegia: by Application(USD Million)
  • Table 5. Ophthalmoplegia Telemedicine Platforms , by Region USD Million (2018-2023)
  • Table 6. Ophthalmoplegia Assistive Technology Application , by Region USD Million (2018-2023)
  • Table 7. Ophthalmoplegia Low Vision Aid Apps , by Region USD Million (2018-2023)
  • Table 8. Ophthalmoplegia: by Treatment(USD Million)
  • Table 9. Ophthalmoplegia Surgery , by Region USD Million (2018-2023)
  • Table 10. Ophthalmoplegia Drug Treatment , by Region USD Million (2018-2023)
  • Table 11. Ophthalmoplegia Other , by Region USD Million (2018-2023)
  • Table 12. South America Ophthalmoplegia, by Country USD Million (2018-2023)
  • Table 13. South America Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 14. South America Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 15. South America Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 16. South America Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 17. Brazil Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 18. Brazil Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 19. Brazil Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 20. Brazil Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 21. Argentina Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 22. Argentina Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 23. Argentina Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 24. Argentina Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 25. Rest of South America Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 26. Rest of South America Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 27. Rest of South America Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 28. Rest of South America Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 29. Asia Pacific Ophthalmoplegia, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 33. Asia Pacific Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 34. China Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 35. China Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 36. China Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 37. China Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 38. Japan Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 39. Japan Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 40. Japan Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 41. Japan Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 42. India Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 43. India Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 44. India Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 45. India Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 46. South Korea Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 47. South Korea Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 48. South Korea Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 49. South Korea Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 50. Taiwan Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 51. Taiwan Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 52. Taiwan Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 53. Taiwan Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 54. Australia Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 55. Australia Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 56. Australia Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 57. Australia Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 58. Rest of Asia-Pacific Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 59. Rest of Asia-Pacific Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 62. Europe Ophthalmoplegia, by Country USD Million (2018-2023)
  • Table 63. Europe Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 64. Europe Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 65. Europe Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 66. Europe Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 67. Germany Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 68. Germany Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 69. Germany Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 70. Germany Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 71. France Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 72. France Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 73. France Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 74. France Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 75. Italy Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 76. Italy Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 77. Italy Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 78. Italy Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 79. United Kingdom Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 80. United Kingdom Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 81. United Kingdom Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 82. United Kingdom Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 83. Netherlands Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 84. Netherlands Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 85. Netherlands Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 86. Netherlands Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 87. Rest of Europe Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 88. Rest of Europe Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 89. Rest of Europe Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 90. Rest of Europe Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 91. MEA Ophthalmoplegia, by Country USD Million (2018-2023)
  • Table 92. MEA Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 93. MEA Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 94. MEA Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 95. MEA Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 96. Middle East Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 97. Middle East Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 98. Middle East Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 99. Middle East Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 100. Africa Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 101. Africa Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 102. Africa Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 103. Africa Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 104. North America Ophthalmoplegia, by Country USD Million (2018-2023)
  • Table 105. North America Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 106. North America Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 107. North America Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 108. North America Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 109. United States Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 110. United States Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 111. United States Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 112. United States Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 113. Canada Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 114. Canada Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 115. Canada Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 116. Canada Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 117. Mexico Ophthalmoplegia, by Type USD Million (2018-2023)
  • Table 118. Mexico Ophthalmoplegia, by Application USD Million (2018-2023)
  • Table 119. Mexico Ophthalmoplegia, by End User USD Million (2018-2023)
  • Table 120. Mexico Ophthalmoplegia, by Treatment USD Million (2018-2023)
  • Table 121. Ophthalmoplegia: by Type(USD/Units)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Ophthalmoplegia: by Type(USD Million)
  • Table 133. Ophthalmoplegia External Ophthalmoplegia , by Region USD Million (2025-2030)
  • Table 134. Ophthalmoplegia Internuclear Ophthalmoplegia , by Region USD Million (2025-2030)
  • Table 135. Ophthalmoplegia: by Application(USD Million)
  • Table 136. Ophthalmoplegia Telemedicine Platforms , by Region USD Million (2025-2030)
  • Table 137. Ophthalmoplegia Assistive Technology Application , by Region USD Million (2025-2030)
  • Table 138. Ophthalmoplegia Low Vision Aid Apps , by Region USD Million (2025-2030)
  • Table 139. Ophthalmoplegia: by Treatment(USD Million)
  • Table 140. Ophthalmoplegia Surgery , by Region USD Million (2025-2030)
  • Table 141. Ophthalmoplegia Drug Treatment , by Region USD Million (2025-2030)
  • Table 142. Ophthalmoplegia Other , by Region USD Million (2025-2030)
  • Table 143. South America Ophthalmoplegia, by Country USD Million (2025-2030)
  • Table 144. South America Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 145. South America Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 146. South America Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 147. South America Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 148. Brazil Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 149. Brazil Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 150. Brazil Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 151. Brazil Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 152. Argentina Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 153. Argentina Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 154. Argentina Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 155. Argentina Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 156. Rest of South America Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 157. Rest of South America Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 158. Rest of South America Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 159. Rest of South America Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 160. Asia Pacific Ophthalmoplegia, by Country USD Million (2025-2030)
  • Table 161. Asia Pacific Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 162. Asia Pacific Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 163. Asia Pacific Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 164. Asia Pacific Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 165. China Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 166. China Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 167. China Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 168. China Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 169. Japan Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 170. Japan Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 171. Japan Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 172. Japan Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 173. India Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 174. India Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 175. India Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 176. India Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 177. South Korea Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 178. South Korea Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 179. South Korea Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 180. South Korea Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 181. Taiwan Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 182. Taiwan Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 183. Taiwan Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 184. Taiwan Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 185. Australia Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 186. Australia Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 187. Australia Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 188. Australia Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 189. Rest of Asia-Pacific Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 190. Rest of Asia-Pacific Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 191. Rest of Asia-Pacific Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 193. Europe Ophthalmoplegia, by Country USD Million (2025-2030)
  • Table 194. Europe Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 195. Europe Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 196. Europe Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 197. Europe Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 198. Germany Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 199. Germany Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 200. Germany Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 201. Germany Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 202. France Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 203. France Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 204. France Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 205. France Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 206. Italy Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 207. Italy Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 208. Italy Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 209. Italy Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 210. United Kingdom Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 211. United Kingdom Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 212. United Kingdom Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 213. United Kingdom Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 214. Netherlands Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 215. Netherlands Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 216. Netherlands Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 217. Netherlands Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 218. Rest of Europe Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 219. Rest of Europe Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 220. Rest of Europe Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 221. Rest of Europe Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 222. MEA Ophthalmoplegia, by Country USD Million (2025-2030)
  • Table 223. MEA Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 224. MEA Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 225. MEA Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 226. MEA Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 227. Middle East Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 228. Middle East Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 229. Middle East Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 230. Middle East Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 231. Africa Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 232. Africa Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 233. Africa Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 234. Africa Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 235. North America Ophthalmoplegia, by Country USD Million (2025-2030)
  • Table 236. North America Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 237. North America Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 238. North America Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 239. North America Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 240. United States Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 241. United States Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 242. United States Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 243. United States Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 244. Canada Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 245. Canada Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 246. Canada Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 247. Canada Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 248. Mexico Ophthalmoplegia, by Type USD Million (2025-2030)
  • Table 249. Mexico Ophthalmoplegia, by Application USD Million (2025-2030)
  • Table 250. Mexico Ophthalmoplegia, by End User USD Million (2025-2030)
  • Table 251. Mexico Ophthalmoplegia, by Treatment USD Million (2025-2030)
  • Table 252. Ophthalmoplegia: by Type(USD/Units)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ophthalmoplegia: by Type USD Million (2018-2023)
  • Figure 5. Global Ophthalmoplegia: by Application USD Million (2018-2023)
  • Figure 6. Global Ophthalmoplegia: by Treatment USD Million (2018-2023)
  • Figure 7. South America Ophthalmoplegia Share (%), by Country
  • Figure 8. Asia Pacific Ophthalmoplegia Share (%), by Country
  • Figure 9. Europe Ophthalmoplegia Share (%), by Country
  • Figure 10. MEA Ophthalmoplegia Share (%), by Country
  • Figure 11. North America Ophthalmoplegia Share (%), by Country
  • Figure 12. Global Ophthalmoplegia: by Type USD/Units (2018-2023)
  • Figure 13. Global Ophthalmoplegia share by Players 2023 (%)
  • Figure 14. Global Ophthalmoplegia share by Players (Top 3) 2023(%)
  • Figure 15. Global Ophthalmoplegia share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott (United States) Revenue: by Geography 2023
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 23. ZEISS International (Germany) Revenue, Net Income and Gross profit
  • Figure 24. ZEISS International (Germany) Revenue: by Geography 2023
  • Figure 25. Valeant Pharmaceuticals International, Inc. (US) Revenue, Net Income and Gross profit
  • Figure 26. Valeant Pharmaceuticals International, Inc. (US) Revenue: by Geography 2023
  • Figure 27. Topcon Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Topcon Corporation (Japan) Revenue: by Geography 2023
  • Figure 29. Medline Industries, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Medline Industries, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 32. Allergan (Ireland) Revenue: by Geography 2023
  • Figure 33. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 35. Santen Pharmaceutical Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Santen Pharmaceutical Co., Ltd (Japan) Revenue: by Geography 2023
  • Figure 37. Global Ophthalmoplegia: by Type USD Million (2025-2030)
  • Figure 38. Global Ophthalmoplegia: by Application USD Million (2025-2030)
  • Figure 39. Global Ophthalmoplegia: by Treatment USD Million (2025-2030)
  • Figure 40. South America Ophthalmoplegia Share (%), by Country
  • Figure 41. Asia Pacific Ophthalmoplegia Share (%), by Country
  • Figure 42. Europe Ophthalmoplegia Share (%), by Country
  • Figure 43. MEA Ophthalmoplegia Share (%), by Country
  • Figure 44. North America Ophthalmoplegia Share (%), by Country
  • Figure 45. Global Ophthalmoplegia: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Novartis AG (Switzerland)
  • Johnson & Johnson (United States)
  • ZEISS International (Germany)
  • Valeant Pharmaceuticals International, Inc. (US)
  • Topcon Corporation (Japan)
  • Medline Industries, Inc. (United States)
  • Allergan (Ireland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Santen Pharmaceutical Co., Ltd (Japan)
Additional players considered in the study are as follows:
Nidek Co., Ltd (Japan) , HOYA Corporation (Japan) , Essilor (France) , Amritt, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 206 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ophthalmoplegia Market Quantitative research analysis
Global Ophthalmoplegia Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Ophthalmoplegia Market are by type [External Ophthalmoplegia and Internuclear Ophthalmoplegia], by end use application [Telemedicine Platforms, Assistive Technology Application and Low Vision Aid Apps].
The Ophthalmoplegia Market is gaining popularity and expected to see strong valuation by 2030.
  • Growing Geriatric Population Worldwide
  • Rising Prevalence of Eye Sight Affecting Diseases

Know More About Global Ophthalmoplegia Market Report?

Have a Query? Click Here

Other Related Reports

Brain Tumor Diagnosis and Treatments Comprehensive Study by Type (Primary Brain Tumor (Meningioma, Gliomas, Astrocytomas, Pituitary Tumors, Other Primary Brain Tumors), Secondary Brain Tumor), Applic...
$ 3750
Tuberculosis Treatment Drugs Comprehensive Study by Type (Active TB, Latent TB), Application (Hospital, Clinic, Durgstore), Drugs (First Line anti-TB Drugs, Second Line anti- TB Drugs) Players and Re...
$ 3500
Acute Disease Comprehensive Study by Type (Acute minor illness (self-limiting), Acute major illness (self-limiting or requiring treatment), Acute presentation of existing major illness (acute exacerb...
$ 3650
Bone Growth Stimulator Comprehensive Study by Application (Spinal Fusion, Delay Union & Non-union Bone Fracture, Oral-maxillofacial, Other Applications), Stimulators (Internal Bone Growth Stimulators...
$ 3750
Cancer Therapeutics Comprehensive Study by Application (Blood cancer, Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Other), Drug Selling (Revlimid, Avastin, Herceptin, Rituxan, Opdi...
$ 3800
Gaucher Disease Treatment Comprehensive Study by Therapy (Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others, Substrate Replacement T...
$ 3750